Polymorphisms of chemokine and chemokine receptor genes in idiopathic immune-mediated posterior segment uveitis

Molecular Vision

Volumn 13, Issue , 2007, Pages 388-396

  Ahad, Muhammad A ^a   Missotten, Tom ^a   Abdallah, Atiyeh ^b   Lympany, Penny A ^b   Lightman, Susan ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CORTICOSTEROID; GENOMIC DNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CAUCASIAN; CHILD; CHROMOSOME 17Q; CHROMOSOME 3P; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ETHNICITY; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC PREDISPOSITION; GENOTYPE; HIGH RISK PATIENT; HUMAN; INTRAOCULAR PRESSURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY; WILD TYPE;

ADOLESCENT; ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHEMOKINES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNE SYSTEM DISEASES; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PHENOTYPE; POLYMORPHISM, GENETIC; RANTES; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; TREATMENT OUTCOME; UVEITIS, POSTERIOR; VISION; VISUAL ACUITY;

EID: 33947602028     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004; 111:491-500;discussion500.
2. Mercanti A, Parolini B, Bonora A, Lequaglie Q, Tomazzoli L. Epidemiology of endogenous uveitis in north-eastern Italy. Analysis of 655 new cases. Acta Ophthalmol Scand 2001; 79:64-8.
3. Tran VT, Auer C, Guex-Crosier Y, Pittet N, Herbort CP. Epidemiology of uveitis in Switzerland. Ocul Immunol Inflamm 1994; 2:169-76.
4. Paivonsalo-Hietanen T, Tuominen J, Vaahtoranta-Lehtonen H, Saari KM. Incidence and prevalence of different uveitis entities in Finland. Acta Ophthalmol Scand 1997; 75:76-81.
5. Dandona L, Dandona R, John RK, McCarty CA, Rao GN. Population based assessment of uveitis in an urban population in southern India. Br J Ophthalmol 2000; 84:706-9.
6. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996; 80:844-8.
7. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996; 80:332-6.
8. Forrester JV, Okada A, BenEzra D, Ohno S, editors. Posterior segment intraocular inflammation guidelines. The Hague: Kugler; 1998.
9. Perkins ES, Folk J. Uveitis in London and Iowa. Ophthalmologica 1984; 189:36-40.
10. Henderly DE, Genstler AJ, Smith RE, Rao NA. Changing patterns of uveitis. Am J Ophthalmol 1987; 103:131-6.
11. Weiner A, BenEzra D. Clinical patterns and associated conditions in chronic uveitis. Am J Ophthalmol 1991; 112:151-8.
12. Rodriguez A, Calonge M, Pedroza-Seres M, Akova YA, Messmer EM, D'Amico DJ, Foster CS. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol 1996; 114:593-9.
13. Boyd SR, Young S, Lightman S. Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol 2001; 46:209-33.
14. Nussenblatt RB. Proctor Lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications. Invest Ophthalmol Vis Sci 1991; 32:3131-41.
15. Calder VL, Shaer B, Muhaya M, Mclauchlan M, Pearson RV, Jolly G, Towler HM, Lightman S. Increased CD4+ expression and decreased IL-10 in the anterior chamber in idiopathic uveitis. Invest Ophthalmol Vis Sci 1999; 40:2019-24.
16. Lacomba MS, Martin CM, Chamond RR, Galera JM, Omar M, Estevez EC. Aqueous and serum interferon gamma, interleukin (IL) 2, IL-4, and IL-10 in patients with uveitis. Arch Ophthalmol 2000; 118:768-72.
17. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2:108-15.
18. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338:436-45.
19. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12:121-7.
20. Elner VM, Burnstine MA, Strieter RM, Kunkel SL, Elner SG. Cell-associated human retinal pigment epithelium interleukin-8 and monocyte chemotactic protein-1: immunochemical and in-situ hybridization analyses. Exp Eye Res 1997; 65:781-9.
21. Verma MJ, Lloyd A, Rager H, Strieter R, Kunkel S, Taub D, Wakefield D. Chemokines in acute anterior uveitis. Curr Eye Res 1997; 16:1202-8.
22. Bian ZM, Elner SG, Strieter RM, Kunkel SL, Lukacs NW, Elner VM. IL-4 potentiates IL-1beta- and TNF-alpha-stimulated IL-8 and MCP-1 protein production in human retinal pigment epithelial cells. Curr Eye Res 1999; 18:349-57.
23. Crane IJ, Kuppner MC, McKillop-Smith S, Knott RM, Forrester JV. Cytokine regulation of RANTES production by human retinal pigment epithelial cells. Cell Immunol 1998; 184:37-44.
24. Elner SG, Elner VM, Bian ZM, Lukacs NW, Kurtz RM, Strieter RM, Kunkel SL. Human retinal pigment epithelial cell interleukin-8 and monocyte chemotactic protein-1 modulation by T-lymphocyte products. Invest Ophthalmol Vis Sci 1997; 38:446-55.
25. Crane IJ, McKillop-Smith S, Wallace CA, Lamont GR, Forrester JV. Expression of the chemokines MIP-1alpha, MCP-1, and RANTES in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2001; 42:1547-52.
26. Elner SG, Strieter RM, Elner VM, Rollins BJ, Del Monte MA, Kunkel SL. Monocyte chemotactic protein gene expression by cytokine-treated human retinal pigment epithelial cells. Lab Invest 1991; 64:819-25.
27. Elner VM, Strieter RM, Elner SG, Baggiolini M, Lindley I, Kunkel SL. Neutrophil chemotactic factor (IL-8) gene expression by cytokine-treated retinal pigment epithelial cells. Am J Pathol 1990; 136:745-50.
28. Crane IJ, Wallace CA, McKillop-Smith S, Forrester JV. Control of chemokine production at the blood-retina barrier. Immunology 2000; 101:426-33.
29. Crane IJ, Xu H, Wallace C, Manivannan A, Mack M, Liversidge J, Marquez G, Sharp PF, Forrester JV. Involvement of CCR5 in the passage of Th1-type cells across the blood-retina barrier in experimental autoimmune uveitis. J Leukoc Biol 2006; 79:435-43.
30. Keino H, Takeuchi M, Kezuka T, Yamakawa N, Tsukahara R, Usui M. Chemokine and chemokine receptor expression during experimental autoimmune uveoretinitis in mice. Graefes Arch Clin Exp Ophthalmol 2003; 241:111-5.
31. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999; 259:344-8.
32. Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, Plunkett BS, Freidhoff LR, Sengler C, Plitt JR, Schleimer RP, Caraballo L, Naidu RP, Levett PN, Beaty TH, Huang SK. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol 2000; 164:1612-6.
33. Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X, Takamatsu JK, Saito H, Ishikawa Y, Akaza T, Juji T, Takebe Y, Ohishi T, Fukutake K, Maruyama Y, Yashiki S, Sonoda S, Nakamura T, Nagai Y, Iwamoto A, Shioda T. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A 1999; 96:4581-5.
34. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998; 352:866-70.
35. Kostrikis LG, Huang Y, Moore JP, Wolinsky SM, Zhang L, Guo Y, Deutsch L, Phair J, Neumann AU, Ho DD. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998; 4:350-3.
36. Hizawa N, Yamaguchi E, Furuya K, Jinushi E, Ito A, Kawakami Y. The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. Am J Respir Crit Care Med 1999; 159:2021-3.
37. Benkirane M, Jin DY, Chun RF, Koup RA, Jeang KT. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem 1997; 272:30603-6.
38. Zapico I, Coto E, Rodriguez A, Alvarez C, Torre JC, Alvarez V. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun 2000; 1:288-9.
39. Petrek M, Cermakova Z, Hutyrova B, Micekova D, Drabek J, Rovensky J, Bosak V. CC chemokine receptor 5 and interleukin-1 receptor antagonist gene polymorphisms in patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2002; 20:701-3.
40. Yang X, Ahmad T, Gogus F, Verity D, Wallace GR, Madanat W, Kanawati CA, Stanford MR, Fortune F, Jewell DP, Marshall SE. Analysis of the CC chemokine receptor 5 (CCR5) Delta32 polymorphism in Behcet's disease. Eur J Immunogenet 2004; 31:11-4. Erratum in: Eur J Immunogenet 2005; 32:219.
41. Chen Y, Vaughan RW, Kondeatis E, Fortune F, Graham EM, Stanford MR, Wallace GR. Chemokine gene polymorphisms associate with gender in patients with uveitis. Tissue Antigens 2004; 63:41-5.
42. Fanning GC, Bunce M, Black CM, Welsh KI. Polymerase chain reaction haplotyping using 3′ mismatches in the forward and reverse primers: application to the biallelic polymorphisms of tumor necrosis factor and lymphotoxin alpha. Tissue Antigens 1997; 50:23-31.
43. Aguilar F, Gonzalez-Escribano MF, Sanchez-Roman J, Nunez-Roldan A. MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus. Tissue Antigens 2001; 58:335-8.
44. Cho ML, Kim JY, Ko HJ, Kim YH, Kim WU, Cho CS, Kim HY, Hwang SY. The MCP-1 promoter -2518 polymorphism in Behcet's disease: correlation between allele types, MCP-1 production and clinical symptoms among Korean patients. Autoimmunity 2004; 37:77-80.
45. Wegscheider BJ, Weger M, Renner W, Posch U, Ulrich S, Hermann J, Ardjomand N, Haller-Schober EM, El-Shabrawi Y. Role of the CCL2/MCP-1 -2518A>G gene polymorphism in HLA-B27 associated uveitis. Mol Vis 2005; 11:896-900.
46. Steinmetz OM, Panzer U, Harendza S, Mertens PR, Ostendorf T, Floege J, Helmchen U, Stahl RA. No association of the -2518 MCP-1 A/G promoter polymorphism with incidence and clinical course of IgA nephropathy. Nephrol Dial Transplant 2004; 19:596-601.
47. Nishimura M, Kuno S, Mizuta I, Ohta M, Maruyama H, Kaji R, Kawakami H. Influence of monocyte chemoattractant protein 1 gene polymorphism on age at onset of sporadic Parkinson's disease. Mov Disord 2003; 18:953-5.
48. Fryer AA, Spiteri MA, Bianco A, Hepple M, Jones PW, Strange RC, Makki R, Tavernier G, Smilie FI, Custovic A, Woodcock AA, Ollier WE, Hajeer AH. The -403 G - >A promoter polymorphism in the RANTES gene is associated with atopy and asthma. Genes Immun 2000; 1:509-14.
49. Makki RF, al Sharif F, Gonzalez-Gay MA, Garcia-Porrua C, Ollier WE, Hajeer AH. RANTES gene polymorphism in polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis. Clin Exp Rheumatol 2000; 18:391-3.
50. Takada T, Suzuki E, Ishida T, Moriyama H, Ooi H, Hasegawa T, Tsukuda H, Gejyo F. Polymorphism in RANTES chemokine promoter affects extent of sarcoidosis in a Japanese population. Tissue Antigens 2001; 58:293-8.
51. Gade-Andavolu R, Comings DE, MacMurray J, Vuthoori RK, Tourtellotte WW, Nagra RM, Cone LA. RANTES: a genetic risk marker for multiple sclerosis. Mult Scler 2004; 10:536-9.
52. Liao CH, Yao TC, Chung HT, See LC, Kuo ML, Huang JL. Polymorphisms in the promoter region of RANTES and the regulatory region of monocyte chemoattractant protein-1 among Chinese children with systemic lupus erythematosus. J Rheumatol 2004; 31:2062-7.
53. Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Ikeda F, Kanno R, Iwashita N, Sakai K, Watada H, Onuma T, Kawamori R. RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. Diabetes Care 2003; 26:892-8.
54. Sonoda KH, Sasa Y, Qiao H, Tsutsumi C, Hisatomi T, Komiyama S, Kubota T, Sakamoto T, Kawano Y, Ishibashi T. Immunoregulatory role of ocular macrophages: the macrophages produce RANTES to suppress experimental autoimmune uveitis. J Immunol 2003; 171:2652-9.
55. Adamus G, Manczak M, Machnicki M. Expression of CC chemokines and their receptors in the eye in autoimmune anterior uveitis associated with EAE. Invest Ophthalmol Vis Sci 2001; 42:2894-903.
56. Petrek M, Drabek J, Kolek V, Zlamal J, Welsh KI, Bunce M, Weigl E, Du Bois R. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2000; 162:1000-3.
57. Miyagishi R, Niino M, Fukazawa T, Yabe I, Kikuchi S, Tashiro K. C-C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 2003; 145:135-8.
58. Lee B, Doranz BJ, Rana S, Yi Y, Mellado M, Frade JM, Martinez- A C, O'Brien SJ, Dean M, Collman RG, Doms RW. Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4. J Virol 1998; 72:7450-8.
59. Vyas S, Kaplan HJ. Age-related macular degeneration associated with C-C chemokine receptor (CCR) 2 genetic polymorphism. ARVO Annual Meeting; 2004 April 25-29; Fort Lauderdale (FL).
60. Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T. A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS 2004; 18:729-38.
61. Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Piao L, Sakai K, Onuma T, Kawamori R. Chemokine receptor genotype is associated with diabetic nephropathy in Japanese with type 2 diabetes. Diabetes 2002; 51:238-42.
62. Hoffmann S, Park J, Jacobson LM, Muehrer RJ, Lorentzen D, Kleiner D, Becker YT, Hullett DA, Mannon R, Kirk AD, Becker BN. Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. Kidney Int 2004; 66:1686-93.
63. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996; 35:3362-7.
64. Crane IJ, Xu H, Manivannan A, McKillop-Smith S, Lamont G, Wallace C, Liversidge J, Sharp PF, Forrester JV. Effect of antimacrophage inflammatory protein-1alpha on leukocyte trafficking and disease progression in experimental autoimmune uveoretinitis. Eur J Immunol 2003; 33:402-10.